ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

ALX Oncology announces the acceptance of two abstracts for poster presentation at the 2024 ASCO Annual Meeting. The abstracts focus on Evorpacept in combination with other therapies for urothelial carcinoma and colorectal cancer. ALX Oncology continues its immuno-oncology developments targeting the CD47 immune checkpoint pathway.

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31-June 4, 2024.

Session titles and information for the two abstracts are listed below and are now available on the ASCO online program planner.

Evorpacept plus enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma: Phase 1a dose escalation results
Session Type and Title: Poster Presentation – Genitourinary Cancer – Kidney and Bladder
Session Date and Time: Sunday, June 2, 2024, 9:00 AM – 12:00 PM CDT
Location: Hall A
Abstract Number: 4575
ALX Oncology Sponsored Clinical Trial

Results of a Phase 2 study of evorpacept (ALX148), and cetuximab, and pembrolizumab in patients with refractory microsatellite stable metastatic colorectal cancer
Session Type and Title: Poster Presentation – Gastrointestinal Cancer – Colorectal and Anal
Session Date and Time: Saturday, June 1, 2024, 1:30 PM – 4:30 PM CDT
Location: Hall A
Abstract Number: 3530
Investigator-Sponsored Trial at the University of Colorado Cancer Center

Copies of the presentations will be available on the Publications section of ALX Oncology’s website following presentation at the meeting.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. To date, evorpacept has been dosed in over 500 subjects and has demonstrated promising activity and favorable tolerability profile across a range of hematologic and solid malignancies in combination with various leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, antibody-drug conjugates (“ADCs”), and PD-1/PD-L1 immune checkpoint inhibitors.

Investor and Media Contact:

Caitlyn Doherty
Manager, Investor Relations and Corporate Communications, ALX Oncology
cdoherty@alxoncology.com
(650) 466-7125

 

FAQ

What is the significance of ALX Oncology's announcement regarding the 2024 ASCO Annual Meeting?

ALX Oncology has announced the acceptance of two abstracts for poster presentation at the 2024 ASCO Annual Meeting, showcasing their ongoing developments in immuno-oncology.

What are the details of the abstracts accepted by ALX Oncology for the poster presentation?

The abstracts focus on Evorpacept plus enfortumab vedotin in urothelial carcinoma and a combination therapy for colorectal cancer, highlighting ALX Oncology's innovative approaches in cancer treatment.

When and where will the poster presentations take place for ALX Oncology at the 2024 ASCO Annual Meeting?

The poster presentations will occur on June 1st and June 2nd, 2024, at the ASCO Annual Meeting in Chicago, specifically in Hall A during the Genitourinary Cancer and Gastrointestinal Cancer sessions.

Where can interested individuals find copies of the presentations following the meeting?

Copies of the presentations will be available on the Publications section of ALX Oncology's website after being presented at the 2024 ASCO Annual Meeting.